Contract Research Solutions for Respiratory Diseases

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Pulmonary Hypertension Model Development Services

Inquiry

Pulmonary hypertension (PH) is a complex and multifactorial disorder that demands robust preclinical models to evaluate novel therapeutic interventions. At Ace Therapeutics, we specialize in the development and validation of custom pulmonary hypertension animal models tailored to your specific research questions. With years of experience in respiratory disease modeling, we provide reliable, reproducible models that closely mimic human pathophysiology, enabling meaningful efficacy assessments and mechanistic studies.

Our Pulmonary Hypertension Models

We offer a diverse portfolio of established and custom PH models across multiple species (rat, mouse). The table below summarizes our most frequently requested models, each can be adapted to meet your specific requirements.

Model Type	Induction Method	Key Features / Applications
Monocrotaline (MCT)-induced	Single subcutaneous or intraperitoneal injection of MCT	Progressive pulmonary vascular remodeling, right ventricular hypertrophy; suitable for testing anti-proliferative and anti-inflammatory compounds.
Chronic Hypoxia (CH)	Exposure to normobaric or hypobaric hypoxia (10% O₂) for 2–4 weeks	Mild-to-moderate PH with muscularization of distal pulmonary arteries; ideal for studying hypoxia-induced pathways and vasodilators.
SU5416 + Hypoxia (SuHx)	Single SU5416 injection (VEGFR2 inhibitor) followed by chronic hypoxia	Severe, progressive PH with plexiform-like lesions; replicates many features of human PAH (Group 1). Excellent for evaluating advanced therapies.
Bleomycin-induced PH	Intratracheal or subcutaneous bleomycin administration	PH secondary to pulmonary fibrosis; useful for testing drugs targeting fibrotic remodeling and associated vascular changes.
Genetic Models	Transgenic or knockout (e.g., Sugen, BMPR2 mutant)	Models with defined genetic backgrounds for studying specific molecular mechanisms (e.g., BMPR2 dysfunction). Custom breeding available.

Note: The above models can be combined with additional challenges (e.g., high-fat diet, aging) to mimic comorbidities. We also offer surgical models (e.g., pulmonary artery banding) upon request.

Comprehensive Preclinical Services Integrated with PH Models

Developing the right model is only the first step. We provide a seamless continuum of services to extract maximum value from your PH model, ensuring robust data to support your drug development program.

Service Category	Specific Assays & Deliverables
In-Life Monitoring & Hemodynamics	Right ventricular systolic pressure (RVSP) measurement via catheterization Mean pulmonary arterial pressure (mPAP) assessment Echocardiography (pulmonary acceleration time, cardiac output) Exercise tolerance (e.g., treadmill, rotarod)
Histopathology & Morphometry	Vascular remodeling assessment (medial wall thickness, muscularization) Right ventricular hypertrophy index (Fulton's index) Immunohistochemistry (e.g., α-SMA, von Willebrand factor, inflammatory markers) Fibrosis quantification (Masson's trichrome, Picrosirius red)
Molecular & Biochemical Analyses	ELISA for cytokine, growth factor, and biomarker profiling Gene expression analysis (qPCR, RNA-seq) for pathways of interest Western blotting for signaling proteins (e.g., RhoA/ROCK, NF-κB) Oxidative stress markers (e.g., malondialdehyde, superoxide dismutase)
Pharmacology & Toxicology Support	PK/PD studies: drug concentration in plasma/tissues, target engagement Dose-range finding and tolerability assessment Combination therapy testing

Our Custom Model Development Approach

We understand that every drug candidate has unique requirements. Our process ensures that the model you receive aligns perfectly with your study objectives.

Consultation: We discuss your target indication, mechanism of action, and desired endpoints to recommend the most appropriate model and study design.
Protocol Development: A detailed study plan is drafted, including animal numbers, dosing schedules, timepoints, and specific readouts. You have full visibility and approval rights.
Model Establishment & Validation: Our experienced in vivo team generates the model, performing pilot runs if necessary to confirm reproducibility and baseline characteristics.
Study Execution: Full-service conduct of your preclinical study, with regular updates and raw data access.
Comprehensive Reporting: Final report includes raw data, statistical analysis, histological images, and expert interpretation.

Why Choose Ace Therapeutics for Your PH Model Development?

Scientific expertise: Our team of PhD-level scientists has extensive hands-on experience in establishing a wide range of PH models, from classic chemically induced to advanced genetic and combination models.
Customization: We work closely with you to design models that reflect the exact subtype and severity of PH relevant to your drug candidate (e.g., Group 1 PAH, Group 3 hypoxia-induced PH).
Comprehensive endpoints: Beyond model generation, we offer a full suite of downstream analyses including hemodynamic measurements, histopathology, molecular biomarkers, and pharmacokinetic/pharmacodynamic (PK/PD) assessments.
Data integrity: All studies are conducted under strict quality control measures, with detailed documentation to support regulatory submissions.

Ready to Advance Your Pulmonary Hypertension Research?

Partner with Ace Therapeutics to access tailored preclinical models and expert services that generate reliable, actionable data. Contact us today to discuss your project and receive a customized proposal.

Frequently Asked Questions (FAQs)

Can you develop a PH model that mimics a specific subtype of pulmonary hypertension (e.g., PAH associated with connective tissue disease)?

Yes, we specialize in customizing models to reflect specific etiologies. For instance, we can combine bleomycin treatment with chronic hypoxia to model PH secondary to interstitial lung disease, or use genetically modified mice to study heritable PAH. Please contact us to discuss your needs.

What is the typical duration of a PH model study?

Study durations vary depending on the model and endpoints. For example, a monocrotaline rat model typically runs 3–4 weeks post-induction, while chronic hypoxia models may last 2–4 weeks. We do not guarantee specific turnaround times, but we will provide a realistic timeline during the planning phase.

What kind of data will I receive at the end of the study?

You will receive a comprehensive report including raw data files (e.g., hemodynamic traces, qPCR results, histology images), statistical analyses, and a detailed description of methods. We also provide an expert summary of the findings and their implications for your drug's efficacy.

Do you offer models in species other than rats and mice?

While our core expertise is in rodent models, we can occasionally support studies in other species (e.g., rabbits) upon special request. Please inquire to explore possibilities.

How do you ensure the reproducibility of your models?

We maintain strict colony management, use age- and weight-matched animals, and adhere to standardized operating procedures for all inductions and measurements. Additionally, we perform pilot studies for new models to establish baseline variability and power calculations.